Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 25;5(4):e56.
doi: 10.2196/mhealth.7226.

Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial Evaluation

Brian M Iacoviello  1   2 , Joshua R Steinerman  1 , David B Klein  1 , Theodore L Silver  1 , Adam G Berger  1 , Sean X Luo  1 , Nicholas J Schork  1   3
Affiliations

Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial Evaluation

Brian M Iacoviello et al. JMIR Mhealth Uhealth. .

Abstract

Background: Tobacco smoking is the leading cause of preventable death in the United States, and the annual economic burden attributable to smoking exceeds US $300 billion. Obstacles to smoking cessation include limited access and adherence to effective cessation interventions. Technology can help overcome these obstacles; many smartphone apps have been developed to aid smoking cessation, but few that conform to the US clinical practice guideline (USCPG) have been rigorously tested and reported in the literature. Clickotine is a novel smartphone app for smoking cessation, designed to deliver the essential features of the USCPG and engineered to engage smokers by personalizing intervention components.

Objective: Our objective was to assess the engagement, efficacy, and safety of Clickotine in an initial, single-arm study. Outcomes measured were indicators of engagement with the smartphone app (number of app opens, number of interactions with the Clickotine program, and weeks active with Clickotine), cessation outcomes of 7- and 30-day self-reported abstinence from smoking, and negative health events.

Methods: We recruited US residents between 18 and 65 years of age who owned an iPhone and smoked 5 or more cigarettes daily for the study via online advertising. Respondents were prescreened for eligibility by telephone and, if appropriate, directed to a Web portal to provide informed consent, confirm eligibility, and download the Clickotine app. Participants completed study assessments via the online portal at baseline and after 8 weeks. Data were collected in Amazon S3 with no manual data entry, and access to all data was maximally restrictive, logged, and auditable.

Results: A total of 416 participants downloaded the app and constituted the intention-to-treat (ITT) sample. On average, participants opened the Clickotine app 100.6 times during the 8-week study (median 69), logged 214.4 interactions with the Clickotine program (median 178), and remained engaged with Clickotine for 5.3 weeks (median 5). Among the ITT sample, 45.2% (188/416) reported 7-day abstinence and 26.2% (109/416) reported 30-day abstinence from smoking after 8 weeks. Completer analysis focused on 365 (87.7%) of the 416 enrolled participants who completed the 8-week questionnaire revealed that 51.5% (188/365) of completers reported 7-day abstinence and 29.9% (109/365) reported 30-day abstinence. Few adverse events, mostly consistent with nicotine withdrawal symptoms, were reported and overall no safety signal was detected.

Conclusions: In this initial single-arm trial, Clickotine users appeared to demonstrate encouraging indicators of engagement in terms of the number of app opens, number of program interactions, and continued engagement over time. Clickotine users reported encouraging quit rates while reporting few adverse events. Future research is warranted to assess Clickotine's efficacy in a randomized controlled trial.

Trial registration: Clinicaltrials.gov NCT02656745; https://clinicaltrials.gov/ct2/show/NCT02656745 (Archived by WebCite at http://www.webcitation.org/6peTT4x60).

Keywords: cigarette smoking; smartphone; smoking cessation; therapeutics; tobacco.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have equity interest in or are employed by Click Therapeutics, Inc., which sponsored the trial and the writing of this manuscript, with the exception of SXL. SXL was compensated for medical monitoring services. JRS has equity interest in and is employed by Teva Pharmaceuticals. Click Therapeutics will make the data from this trial available to qualified researchers upon request for independent analysis.

Figures

Figure 1
Figure 1
Examples of interactions with the Clickotine program (left to right, beginning at top): choose a quit date; log cravings; mission: share quit date with supporters; learn about quit aids; control breathing; receive a personalized message.
Figure 2
Figure 2
Study flow diagram. ITT: intention-to-treat.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention Smoking & tobacco use fast facts. 2016. [2017-02-27]. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/
    1. U.S. Department of Health and Human Services The health consequences of smoking-50 years of progress: a report of the Surgeon General. 2014. [2016-12-22]. https://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm .
    1. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current Cigarette Smoking Among Adults - United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205–11. doi: 10.15585/mmwr.mm6544a2. doi: 10.15585/mmwr.mm6544a2. - DOI - DOI - PubMed
    1. U.S. Department of Health and Human Services Preventing tobacco use among youth and young adults. 2012. [2016-12-22]. https://www.surgeongeneral.gov/library/reports/preventing-youth-tobacco-...
    1. Xu X, Bishop EE, Kennedy SM, Simpson SA, Pechacek TF. Annual healthcare spending attributable to cigarette smoking: an update. Am J Prev Med. 2015 Mar;48(3):326–33. doi: 10.1016/j.amepre.2014.10.012. http://europepmc.org/abstract/MED/25498551 S0749-3797(14)00616-3 - DOI - PMC - PubMed

Associated data